The September/October issue is live! 👀 🧠 Visual training & presbyopia IOLs 🧬 Retesting for IRDs 🔧 Yamane vs Gore-Tex 🤖 AI in retinal disease Check Out the September/October Issue on Ophthalmology Times Europe 👇 hubs.li/Q04C85Tx0

Did you miss it? The full SPECTRUM Rapid Readout series is here—real-world vision, anatomic, and safety outcomes with high-dose anti-VEGF therapy in wet AMD, with Javier Zarranz-Ventura, MD, PhD. Catch Up ⬇️ hubs.li/Q04tbKp40

Examine how #ArtelacComplete, a preservative-free, multicomponent #tearsubstitute designed to support multiple layers of the #tearfilm, performs where it matters most. Learn More: hubs.li/Q04zX3Sg0

Subretinal RPE cells for GA: ~11-letter gains held at 18 months in phase 1. #EURETINA2026 hubs.li/Q04zhjXt0

EYP-1901 missed LUGANO’s primary endpoint, yet cut treatment burden by 42%. Roger Goldberg, MD, explains why at #EURETINA2026. hubs.li/Q04zhj2Q0

EURETINA 2026: Serena Salvatore, MD, on the retinal laser training gap, persistent laser myths, and how simulation can support safer treatment. hubs.li/Q04z5q-P0

Uveitis or retinitis pigmentosa? At EURETINA 2026, Ester Carreño, MD, PhD, explains how to tell them apart and why genetic confirmation matters more now. hubs.li/Q04z5r0y0

EURETINA 2026: Arshad Khanani, MD, reviews 2-year SPECTRA data on 4D-150 gene therapy in DMO and the phase 3 4SIGHT trial against aflibercept. hubs.li/Q04z5qLl0

Ahead of #EURETINA2026 in Vienna (Oct 1-4), Anat Loewenstein, MD previews the Innovation Spotlight, 17 invited-lecture sessions & new World Retina programming. hubs.li/Q04xY5PH0

Fluid resolution. Safety signals. No retinal vasculitis. Javier Zarranz-Ventura, MD, PhD, reviews SPECTRUM’s real-world safety data on high-dose anti-VEGF therapy in wet AMD. Watch Episode 2 ⬇️ hubs.li/Q04tb_CV0 #nAMD #Retina #AntiVEGF

ESCRS 2026: Tecnis PureSee EDOF IOL delivers comparable near vision & spectacle independence in post-LASIK vs non-LASIK eyes, per David Mingo Botín, MD, PhD. hubs.li/Q04xDBfr0

ESCRS 2026: Citicoline eye drops speed corneal nerve/sensitivity recovery after cataract surgery, per Suzana Konjevoda, MD — significant gains by 3 weeks. hubs.li/Q04xDB4S0

ESCRS 2026: Diffractive multifocal IOLs tie on distance vision, but reading speed plunges to ~30 wpm in dim light, study finds. hubs.li/Q04xDB7p0

ESCRS 2026: Radhika Rampat, MBBS, FRCOphth, on bringing low-level light therapy into refractive practice—from dry eye to chalazion care. hubs.li/Q04xDB1_0

ESCRS 2026: Corneal measurements shift across the day — early-morning readings may be biased by overnight eyelid closure, new data show. hubs.li/Q04xDB500

ESCRS 2026: enVista Aspire monofocal-plus IOL gives near-20/20 distance + functional intermediate vision in 90%+ of patients. hubs.li/Q04xDz_y0

ESCRS 2026: 3-year data show trans-epithelial PRK matches conventional PRK on safety, outcomes & comfort — with faster surgical time. hubs.li/Q04xDzvY0

ESCRS 2026: Real-world aceclidine (VIZZ) data show near-vision gains within 15-30 min, lasting ~6 hrs for many presbyopia patients. hubs.li/Q04xDz4f0

Day 1 of the 44th Congress of the ESCRS is underway at the ExCeL Exhibition Centre, for five days of clinical sessions, surgical education and networking along the banks of the River Thames. hubs.li/Q04xcKVd0

Real-world data on aflibercept 8 mg in wet AMD is here. Javier Zarranz-Ventura, MD, PhD, breaks down week 12 SPECTRUM study outcomes—3.8-letter mean VA gain in treatment-naive eyes. Watch Episode 1: hubs.li/Q04t32cR0 #nAMD #Retina #AntiVEGF